185408-97-3

Basic information

• Product Name: 1H-Purin-6-amine, 2-chloro-N-phenyl-
• CAS NO: 185408-97-3
• Molecular Formula: C11H8ClN5
• Molecular Weight: 245.671
• Mol File: 185408-97-3.mol
• Article Data: 17

Chemical Properties

• CAS DataBase Reference: 1H-Purin-6-amine, 2-chloro-N-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Purin-6-amine, 2-chloro-N-phenyl-(185408-97-3)
• EPA Substance Registry System: 1H-Purin-6-amine, 2-chloro-N-phenyl-(185408-97-3)

Safety Data

• Hazardous Substances Data: 185408-97-3(Hazardous Substances Data)

Upstream product

• 62-53-3 aniline 
• 5451-40-1 2,6-dichloro-7H-purine 
• 10310-21-1 2-Amino-6-chloropurin 
• 73-40-5 2-amino-6-hydroxypurine 
• 97965-44-1 2-acetamido-9-acetyl-6-chloropurine 
• 5451-40-1 2,6 dichloropurine 

Downstream Products

• 1338807-93-4 2-p-chloroaniline-6-anlilinepurine 
• 1338807-94-5 2-p-methoxyaniline-6-anlilinepurine 
• 52819-68-8 2,6-dianlilinepurine 
• 310401-64-0 2-chloro-9-cyclopentyl-N-phenyl-9H-purin-6-amine 
• 203436-33-3 2-chloro-9-isopropyl-N-phenyl-9H-purin-6-amine 

Relevant articles and documents

Pyrimido five-membered heterocyclic compound and application as mutant IDH2 inhibitor

The invention relates to a pyrimido five-membered heterocyclic compound and an application of the pyrimido five-membered heterocyclic compound as a mutant IDH2 inhibitor, and specifically discloses apyrimido five-membered heterocyclic compound capable of being used as a mutant IDH2 inhibitor, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, a hydrate or a solvate thereof. The invention also relates to a pharmaceutical composition containing the compound, and application of the pharmaceutical composition in preparation of drugs for preventing and/or treating mutantIDH2 mediated diseases.

Syntheses and biological evaluation of novel hydroxamic acid derivatives containing purine moiety as histone deacetylase inhibitors

The novel hydroxamates containing purine scaffold were designed, synthesized and screened for their biological activities as histone deacetylase (HDAC) inhibitors. Some of them exhibited excellent acti-HDACs activities and antiproliferative activities, th

Discovery of Multitarget Antivirals Acting on Both the Dengue Virus NS5-NS3 Interaction and the Host Src/Fyn Kinases

This study describes the discovery of novel dengue virus inhibitors targeting both a crucial viral protein-protein interaction and an essential host cell factor as a strategy to reduce the emergence of drug resistance. Starting from known c-Src inhibitors